HERBARIUM
Europe
is not moving in one direction.
That is the first thing to understand. There is no single European cannabis story.
Some countries are liberalising, some are experimenting and others are tightening control. Several are doing all three at once.
This is not a contradiction.
It is Europe.
European cannabis reform is not a clean march from prohibition to freedom. It is an argument between public health, criminal law, medical access, youth protection, markets, borders and bureaucracy.
So the right question is not:
Is Europe legalising cannabis?
The better question is:
What kind of control is Europe trying to keep
while it legalises parts of it?
Because Europe may not be returning to prohibition.
But it is trying very hard not to lose control.
The European Union does not have
a single adult-use cannabis law.
Cannabis policy remains largely national. European countries differ on possession, home cultivation, medical access, cultivation associations, pilot projects, penalties and legal supply. Germany permits limited possession, home cultivation and non-profit cultivation associations; Switzerland operates controlled scientific pilot trials; and the Netherlands is testing a regulated supply chain for participating coffeeshops.
That matters because any sentence beginning with “Europe is doing…” is probably too simple.
Europe is not doing one thing.
Europe is negotiating with itself.
Germany is the clearest
modern example.
Germany’s 2024 reform permits adults to possess up to 25 grams in public, retain up to 50 grams at home, cultivate up to three plants and participate in tightly regulated non-profit cultivation associations.
It was significant reform, but not a commercial dispensary model.
Germany did not simply open dispensaries and let the market run. Its model is cautious, limited, non-profit-oriented, heavily regulated and politically contested.
Then came the medical side.
Germany also illustrates how reform creates new disputes around medical prescribing, remote consultations, imports, supply and commercial behaviour. Opening one legal route does not end regulation; it moves political conflict into the design of that route.
This is the European pattern in miniature:
Germany did not simply “legalise cannabis”.
Germany legalised parts of cannabis while trying to keep the medical system, youth protection, supply and public order under control.
Legalisation is not the end of control.
It is the beginning of a new argument about control.
Europe’s tightening mood
is not random.
It comes from several fears at once.
The tightening is driven by concerns about potency, youth exposure, medical-system abuse, driving, commercialisation, organised crime, cross-border supply and synthetic or semi-synthetic cannabinoids.
The European Drug Report 2026 reports that cannabis resin seized in the European Union in 2024 contained an average of 24.6% THC, compared with 12% for herbal cannabis. These averages conceal substantial variation between products and countries
That gives policymakers a powerful argument:
“Some contemporary products differ significantly from those on which older assumptions were based.”
Sometimes that argument is used carefully.
Sometimes it becomes panic.
But the concern is real enough
that serious education cannot ignore it.
Europe is also worried about synthetic
and semi-synthetic cannabinoids.
European monitoring also describes an expanding market for new psychoactive substances, including synthetic and semi-synthetic cannabinoids. These products may exploit regulatory gaps and should not be treated as equivalent to conventional cannabis merely because they are marketed beside it.
This matters because regulators
often respond to the most frightening edge cases.
An adulterated edible, an unidentified vape, a medical-prescribing controversy or a case involving a young person can quickly tighten the entire cannabis debate.
Then the whole cannabis conversation tightens. The danger is that real risks become excuses for blunt policy.
The opposite danger is that cannabis advocates dismiss real risks because they fear prohibition returning.
Both are mistakes.
The answer to panic is not denial.
It is better regulation, better testing and better education.
Europe can make a policy progressive on paper
and useless in practice.
This is the danger. If legal access is too expensive, too slow, too bureaucratic, too limited or too confusing, people return to the old channels.
If medical access becomes a theatre of paperwork, patients may return to informal sources. If cultivation associations are nearly impossible to operate, illegal suppliers retain the market. If legal products are scarce or unaffordable, unregulated products remain attractive. If home cultivation is permitted without education, people learn through rumour rather than agronomy.
This is the core European risk:
Overregulation can become prohibition
with better manners.
But if it fails to create realistic, safer pathways, it still feeds the market it claims to fight.
If legal access becomes harder than illegal access,
the black market thanks the regulator.
Europe should not blindly copy
the United States.
American reform produced patient access, political experimentation and commercial innovation, but also over-commercialisation, unequal participation, tax problems, regulatory conflict and market concentration.
Europe is right to be cautious.
But caution is not the same as paralysis.
The lesson is not:
“Copy America.”
The lesson is:
“Learn from American courage
without importing every American mistake”.
Europe should avoid a purely commercial cannabis future. But it should also avoid suffocating reform so badly that only criminals, grey markets and loophole operators can move freely.
A good cannabis policy must be strict where harm is real and practical
where human behaviour is predictable.
The Netherlands gave Europe
its most famous cannabis model:
coffeeshop tolerance.
The Dutch coffeeshop system historically tolerated retail under conditions while leaving much of the supply chain illegal—the familiar “front door/back door” problem. Since April 2025, participating municipalities have entered the experimental phase of a controlled supply-chain project intended to test regulated production and distribution
That is not a complete system.
It is a compromise.
Historically, that compromise mattered. It helped separate cannabis from harder drug markets and created a visible alternative to criminalisation. But it also showed the danger of half-policy: if retail is tolerated but supply remains illegal, criminal networks keep part of the system.
This is a lesson for Europe now.
Partial reform can reduce harm.
But unfinished reform leaves shadows.
Medical cannabis
is where Europe’s contradiction
becomes most painful.
Medical access can become slow, expensive and inconsistent. Rules that are too loose may weaken clinical credibility; rules that are too restrictive may abandon genuine patients.
Medical cannabis should not be a loophole.
It should also not be a maze.
Youth protection
is the most powerful argument
in European cannabis politics.
And it should be. Young brains, high-THC products, early frequent use, mental-health vulnerability and social normalisation are serious issues. Any honest cannabis education must say so.
But “protect the youth” can become lazy
if it only means punishment, silence or fear.
Young people do not become safer because adults refuse to explain potency, delayed edible effects, impaired driving, substance mixing, dependence, contamination and mental-health risk.
They become safer when adults tell the truth early enough to matter. A mature cannabis policy must separate three things:
If Europe uses youth protection only to justify control, it will miss the educational responsibility.
Silence does not protect young people.
It only decides who teaches them instead.
Europe’s cannabis future
will not be decided only by whether
laws become softer or harder.
It will be decided by whether legal systems become more credible than illegal ones. That means:
Clean products, credible testing, fair medical access, realistic legal supply, clear labelling, youth education, worker protection, environmental standards, non-commercial options and enforcement against exploitation.
The black market does not disappear
because a parliament passed a law.
It declines only when legal pathways become safer, more trustworthy
and practical enough to compete.
Europe’s danger is not simply that it may become too strict.
Europe’s danger is that it may become strict
in the wrong places and weak in the places that matter.
Europe is not simply going
backwards.
But it is tightening.
Not everywhere, not in one form and not always wrongly. Control is being redesigned around access, prescribing, potency, youth exposure, legal supply and emerging cannabinoid products.
Some of this is necessary.
Some of it may become cowardice.
The dividing line is simple:
Does the rule create a safer, more accountable pathway?
Or does it push people back into the dark?
That is the test.
Factual Note
Europe does not have one unified adult-use cannabis regime. National approaches range from criminal prohibition and decriminalisation to home cultivation, non-profit associations, toleration systems and controlled pilot projects.
Germany’s 2024 reform permits limited possession, private cultivation and regulated non-profit cultivation associations. Switzerland’s non-medical cannabis access remains confined to authorised scientific pilot trials. In the Netherlands, the experimental phase of the controlled coffeeshop supply-chain project began on 7 April 2025 in participating municipalities.
According to the European Drug Report 2026, the average THC content of cannabis resin seized in the European Union in 2024 was 24.6%, compared with 12% for herbal cannabis. These figures describe averages from seized material and should not be applied to every product or national market.
Reform and tighter regulation can occur simultaneously. Whether tightening reduces harm or strengthens unregulated supply depends on implementation, affordability, access, product standards and the credibility of legal pathways.
A living archive of cannabis—its cultivation in practice and its traces across science, culture, language, power and memory.
Join early.
Keep the archive open.
The VADEMECUM is becoming a living archive of guides, tools, notes and practical plant knowledge.
Free member access. Join early. Keep the archive open.
Join early.
Keep the
archive open.
The VADEMECUM is not just a book anymore. It is becoming a living archive of guides, tools, notes and practical plant knowledge.
Free member access. Join early. Keep the archive open.
The VADEMECUM is becoming a living archive of practical plant knowledge.
Free member access.